In a separate double-blinded placebo-controlled study in drug-naïve T2DM patients, Matikainen et al. [107] demonstrated that 4-weeks therapy with another DPP-4 inhibitor, vildagliptin, also decreased postprandial TG levels (Table 2). Here, DPP4 is linked to type 2 diabetes mellitus.